Joseph R. Berger

Joseph R. Berger

Auto-generated profile, based on publicly available information

Joseph R. Berger

Department of Neurology University of Pennsylvania Philadelphia PA USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2013 in Neurology
Verified
Journal Article
Closed access
PDF file
JBJoseph R. Berger
Joseph R. Berger
AAAllen J. Aksamit
Allen J. Aksamit
DCDavid B. Clifford
David B. Clifford
LDLarry Davis
Larry Davis
IKIgor J. Koralnik
Igor J. Koralnik
ANAvindra Nath
Avindra Nath
Objective: To establish criteria for the diagnosis of progressive multifocal leukoencephalopathy (PML). Methods: We reviewed available literature to identify various diagnostic criteria employed. Several search strategies employing the terms “progressive multifocal leukoencephalopathy” with or without “JC virus” were performed with PubMed, SCOPUS, and EMBASE search engines. The articles were reviewed by a committee of individuals with expertise in the disorder in order to determine the most useful applicable criteria. Results: A consensus statement was developed employing clinical, imaging, pathologic, and virologic evidence in support of the diagnosis of PML. Two separate pathways, histopathologic and clinical, for PML diagnosis are proposed. Diagnostic classification includes certain, probable, possible, and not PML. Conclusion: Definitive diagnosis of PML requires neuropathologic demonstration of the typical histopathologic triad (demyelination, bizarre astrocytes, and enlarged oligodendroglial nuclei) coupled with the techniques to show the presence of JC virus. The presence of clinical and imaging manifestations consistent with the diagnosis and not better explained by other disorders coupled with the demonstration of JC virus by PCR in CSF is also considered diagnostic. Algorithms for establishing the diagnosis have been recommended.

1 February 2017 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
JBJoseph R. Berger
Joseph R. Berger

1 April 2020 in Journal of NeuroVirology
Verified
Journal Article
Closed access
JBJoseph R. Berger
Joseph R. Berger

1 May 2008 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
JBJoseph R. Berger
Joseph R. Berger
SHSidney Houff
Sidney Houff
Review from JAMA Neurology — Neurological Complications of Herpes Simplex Virus Type 2 Infection

15 May 2018 in Neurology
Verified
Journal Article
Open access
PDF file
JBJoseph R. Berger
Joseph R. Berger
BCBruce A. Cree
Bruce A. Cree
BGBenjamin Greenberg
Benjamin Greenberg
BHBernhard Hemmer
Bernhard Hemmer
BWBrian J. Ward
Brian J. Ward
MMMartin Merschhemke
Martin Merschhemke
Objective We describe the characteristics of the 15 patients with fingolimod-associated progressive multifocal leukoencephalopathy (PML) identified from the Novartis data safety base and provide risk estimates for the disorder. Methods The Novartis safety database was searched for PML cases with a data lock point of August 31, 2017. PML classification was based on previously published criteria. The risk and incidence were estimated using the 15 patients with confirmed PML and the overall population of patients treated with fingolimod. Results As of August 31, 2017, 15 fingolimod-treated patients had developed PML in the absence of natalizumab treatment in the preceding 6 months. Eleven (73%) were women and the mean age was 53 years (median: 53 years). Fourteen of the 15 patients were treated with fingolimod for >2 years. Two patients had confounding medical conditions. Two patients had natalizumab treatment. This included one patient whose last dose of natalizumab was 3 years and 9 months before the diagnosis of PML. The second patient was receiving fingolimod for 4 years and 6 months, which was discontinued to start natalizumab and was diagnosed with PML 3 months after starting natalizumab. Absolute lymphocyte counts were available for 14 of the 15 patients and none exhibited a sustained grade 4 lymphopenia (≤200 cells/μL). Conclusions The risk of PML with fingolimod in the absence of prior natalizumab treatment is low. The estimated risk was 0.069 per 1,000 patients (95% confidence interval: 0.039–0.114), and the estimated incidence rate was 3.12 per 100,000 patient-years (95% confidence interval: 1.75–5.15). Neither clinical manifestations nor radiographic features suggested any unique features of fingolimod-associated PML.

5 March 2018 in Journal of NeuroVirology
Verified
Journal Article
Open access
PDF file
JBJoseph R. Berger
Joseph R. Berger
VMVineeta Malik
Vineeta Malik
SLStuart Lacey
Stuart Lacey
PBPaul Brunetta
Paul Brunetta
PLPatricia B. Lehane
Patricia B. Lehane
This report assesses the observed risk of PML in patients treated with the anti-CD20 monoclonal antibody rituximab in the regulatory authority-approved autoimmune indications rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). This was a cumulative analysis of confirmed PML cases in patients receiving rituximab for RA or GPA/MPA from both spontaneous reports and clinical trial sources, as captured in the manufacturer global company safety and clinical databases. Overall reporting rates were calculated and patient case details were summarized. As of 17 November 2015, there were nine confirmed PML cases among patients who had received rituximab for RA and two for GPA. Corresponding estimated reporting rates were 2.56 per 100,000 patients with RA (estimated exposure ≈ 351,396 patients) and < 1 per 10,000 patients with GPA/MPA (estimated exposure 40,000–50,000 patients). In all cases, patients had ≥ 1 potential risk factor for PML independent of rituximab treatment. In the RA population, the estimated reporting rate of PML generally remained stable and low since 2009 despite increasing rituximab exposure. There was no pattern of latency from time of rituximab initiation to PML development and no association of PML with the number of rituximab courses. Global post-marketing safety and clinical trial data demonstrated that the occurrence of PML is very rare among rituximab-treated patients with RA or GPA/MPA and has remained stable over time.